Study: Meso treatment success determined by surgery intervals

16 Jun 2017 by under Research/Treatment

598px Chemotherapy vials 3 100x100 Study: Meso treatment success determined by surgery intervalsResearchers from the City of Hope Cancer Center and the Wake Forest School of Medicine believe they have uncovered information about how surgery success factors into peritoneal mesothelioma patients’ overall survival time.

The team analyzed database information for 1,314 patients who had cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) between February 1993 and December 2015 and then focused on 103 patients who had the procedure repeated and determined those who survive more than two years after their initial surgery are most likely to benefit from a second surgery, according to Surviving .

“Although cancer eventually returned for all patients, those who went the longest without recurrence after the first surgery also ended up experiencing the longest overall survival after their second procedure,” the news source reports.

CRS/HIPEC is considered the “gold standard” in the treatment of , a cancer that affects the lining of the abdomen. The surgery, which removes as much mesothelioma from the abdomen as possible, is followed by a wash of heated chemotherapy medication to kill any remaining cells.

The overall median survival time for patients in the study was 4.3 years. More than 20 percent needed to repeat CRS/HIPEC after a year, and in two years 38 percent of the patients required a repeat surgery. The 42 patients who survived more than two years before undergoing CRS/HIPEC had the best outcomes after the second surgery as well.

“In multivariate analysis, the R status [a measure of the completeness of the tumor removal] and a time interval of more than two years were strongly associated with survival with each additional month between the surgeries conferring a 2.6 percent reduction in the risk of death,” the researchers wrote.


Comments are closed.